Pharsight

Drugs that contain Avapritinib

1. Ayvakit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9944651 BLUEPRINT MEDICINES Compositions useful for treating disorders related to kit
Oct, 2034

(10 years from now)

US9994575 BLUEPRINT MEDICINES Compositions useful for treating disorders related to kit
Oct, 2034

(10 years from now)

US9200002 BLUEPRINT MEDICINES Compositions useful for treating disorders related to KIT
Oct, 2034

(10 years from now)

US11827642 BLUEPRINT MEDICINES Compositions useful for treating disorders related to KIT
Oct, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) May 22, 2026
New Chemical Entity Exclusivity (NCE) Jan 9, 2025
Orphan Drug Exclusivity (ODE) Jan 9, 2027

NCE-1 date: 2024-01-10

Market Authorisation Date: 09 January, 2020

Treatment: Treatment of unresectable or metastatic gastrointestinal stromal tumor (gist) harboring a platelet-derived growth factor receptor alpha (pdgfra) exon 18 mutation; Treatment of advanced systemic mastoc...

Dosage: TABLET;ORAL

More Information on Dosage

AYVAKIT family patents

Family Patents